IMUX - IMMUNIC, INC.

10.75
0.770   7.163%

Share volume: 375,270
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$9.98
0.77
0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 8%
Dept financing 3%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1,121.45%
1 Month
943.69%
3 Months
1,662.30%
6 Months
1,247.46%
1 Year
739.84%
2 Year
773.98%
Key data
Stock price
$10.75
P/E Ratio 
0.00
DAY RANGE
$9.58 - $10.91
EPS 
-$0.62
52 WEEK RANGE
$0.51 - $10.91
52 WEEK CHANGE
$985.75
MARKET CAP 
64.196 M
YIELD 
N/A
SHARES OUTSTANDING 
130.465 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
1.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,058,279
AVERAGE 30 VOLUME 
$2,652,435
Company detail
CEO: Daniel Vitt
Region: US
Website: immunic-therapeutics.com
Employees: 70
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.

Recent news